concept

SUBSTANTIA NIGRA

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SUBSTANTIA NIGRA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

768Connections

4Hypotheses

2Analyses

50Outgoing

50Incoming

0Experiments

2Debates

Summary

SUBSTANTIA NIGRA is a concept in neurodegeneration research. Key relationships include: co discussed, associated with, regulates. Associated with PARKINSON, PARKINSON'S, PARKINSON'S DISEASE. Connected to 79 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	SUBSTANTIA NIGRA
Key Genes/Proteins	AIF1, AKT, ALPHA-SYNUCLEIN, AMPK, AMYLOID, APP
Related Diseases	ALZHEIMER'S DISEASE, APOPTOSIS, ATP
Related Pathways	AMPK SIGNALING

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Substantia Nigra Neurons

cell · 821 words

→

Pathway Diagram

graph TD
    SUBSTANTIA_NIGRA["SUBSTANTIA NIGRA"]
    SUBSTANTIA_NIGRA -->|"interacts"| Dopamine["Dopamine"]
    dopaminergic_neurons["dopaminergic neurons"] -->|"expressed in"| SUBSTANTIA_NIGRA
    Dopamine -->|"interacts"| SUBSTANTIA_NIGRA
    lipopolysaccharide["lipopolysaccharide"] -->|"activates"| SUBSTANTIA_NIGRA
    GCASE["GCASE"] -->|"expressed in"| SUBSTANTIA_NIGRA
    NEURON["NEURON"] -->|"expressed in"| SUBSTANTIA_NIGRA
    PARKINSON_S_DISEASE["PARKINSON'S DISEASE"] -->|"expressed in"| SUBSTANTIA_NIGRA
    PARKINSON["PARKINSON"] -->|"expressed in"| SUBSTANTIA_NIGRA
    PLIN2["PLIN2"] -->|"expressed in"| SUBSTANTIA_NIGRA
    NEURODEGENERATION["NEURODEGENERATION"] -->|"expressed in"| SUBSTANTIA_NIGRA
    ALPHA_SYNUCLEIN["ALPHA-SYNUCLEIN"] -->|"expressed in"| SUBSTANTIA_NIGRA

Outgoing (163)

Target	Relation	Type	Str
dopamine-producing neurons	expressed_in	cell_type	0.90
Dopamine	activates	entity	0.70
L-DOPA	inhibits	drug	0.70
Dopamine	interacts_with	entity	0.70
Dopamine	regulates	entity	0.70
NAD+ decline	associated_with	process	0.70
DOPAMINERGIC NEURONS	stabilizes	cell_type	0.70
STROKE	regulates	disease	0.70
GLIOSIS	inhibits	phenotype	0.65
PARKINSON'S DISEASE	treats	disease	0.65
NEURODEGENERATION	activates	disease	0.65
OXIDATIVE STRESS	activates	phenotype	0.65
SYNAPTIC PLASTICITY	regulates	phenotype	0.65
UBIQUITIN	transports	protein	0.65
BASAL GANGLIA	causes	brain_region	0.65
TH	causes	gene	0.65
GLIOSIS	interacts_with	phenotype	0.65
TH	regulates	gene	0.60
Parkinson	loss_affects	disease	0.60
PARKINSON'S	inhibits	concept	0.50
ST3GAL2	inhibits	concept	0.50
GENE EXPRESSION	inhibits	concept	0.50
DOPAMINERGIC	causes	concept	0.50
DOPAMINERGIC NEURONS	causes	concept	0.50
DOPAMINERGIC NEURONS	associated_with	concept	0.50
PARKINSON'S	interacts_with	concept	0.50
DOPAMINERGIC	inhibits	concept	0.50
DOPAMINE	inhibits	concept	0.50
DOPAMINERGIC NEURONS	inhibits	concept	0.50
DOPAMINE	associated_with	concept	0.50
DOPAMINERGIC	activates	concept	0.50
STRIATUM	activates	concept	0.50
DOPAMINERGIC NEURONS	activates	concept	0.50
PI3K/AKT/mTOR	activates	pathway	0.50
Proteins	activates	protein	0.50
MTOR SIGNALING	activates	concept	0.50
STRIATUM	associated_with	concept	0.50
AADC	activates	concept	0.50
PARKINSON'S	expressed_in	concept	0.50
ST3GAL2	expressed_in	concept	0.50
GENE EXPRESSION	expressed_in	concept	0.50
Proteins	associated_with	protein	0.50
PREFRONTAL CORTEX	activates	concept	0.50
Microbiota	inhibits	process	0.50
Gut Microbiota	inhibits	process	0.50
SYNAPTIC PLASTICITY	co_discussed	entity	0.50
VENTRAL TEGMENTAL AREA	activates	brain_region	0.50
PARKINSON'S	causes	concept	0.50
SYNUCLEIN	causes	concept	0.50
DOPAMINE	causes	concept	0.50

Incoming (605)

Source	Relation	Type	Str
MICROGLIA	associated_with	cell_type	1.00
PARKINSON'S DISEASE	associated_with	disease	1.00
DOPAMINERGIC NEURONS	causes	cell_type	0.95
DOPAMINERGIC NEURONS	associated_with	cell_type	0.95
DOPAMINERGIC NEURONS	expressed_in	cell_type	0.95
Parkinson's Disease	associated_with	disease	0.95
m6A deficiency	associated_with	process	0.90
40135662	are enriched in	paper	0.90
Parkinson's disease	affects	disease	0.90
neurodegeneration	affects	disease	0.90
alpha-synuclein	causes	protein	0.90
Tyrosine Hydroxylase	expressed_in	enzyme	0.90
METTL3	expressed_in	gene	0.90
MN	associated_with	compound	0.90
Parkinson'S Disease	associated_with	disease	0.90
LEPTIN	expressed_in	protein	0.90
FE	associated_with	compound	0.90
IL-6	expressed_in	protein	0.90
PARK2 Deficiency	causes	phenotype	0.88
Reduced Gangliosides	biomarker_for	biomarker	0.85
MCH	expressed_in	protein	0.85
SNCA	causes	protein	0.85
MCH Neurons	expressed_in	cell_type	0.85
PARKIN	associated_with	gene	0.82
REV-ERBα	expressed_in	protein	0.80
TH	expressed_in	gene	0.80
neuroinflammation	affects	disease	0.80
TP53	expressed_in	gene	0.75
TNF	associated_with	gene	0.74
NF-KB	associated_with	protein	0.74
TREM2	expressed_in	gene	0.70
lipopolysaccharide	activates	drug	0.70
TFEB	regulates	gene	0.70
ASC	expressed_in	gene	0.70
TFEB	protects_against	gene	0.70
unfolded protein response	active_in	pathway	0.70
Dopamine	interacts_with	entity	0.70
enteric nervous system	regulates	brain_region	0.70
dopaminergic neurons	expressed_in	cell_type	0.70
BDNF	protects_against	gene	0.70
AUTOPHAGY	causes	phenotype	0.70
Parkinson's disease	associated_with	disease	0.70
PARKINSON'S DISEASE	causes	disease	0.66
AUTOPHAGY	inhibits	process	0.66
TREM2	associated_with	gene	0.66
ASTROCYTES	associated_with	cell_type	0.66
MTOR	associated_with	gene	0.66
IL-1B	associated_with	gene	0.66
NEURON	sensitizes_to	cell_type	0.65
NEURONS	sensitizes_to	cell_type	0.65

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
m6A-dependent control of alpha-synuclein transcript fate and	0.626	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Cell-state stratification is required to resolve m6A RNA Mod	0.612	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	m6A RNA Modification and Alpha-Synuclein
AAV-Mediated RGS6 Overexpression in Substantia Nigra Parvoce	0.424	neurodegeneration	Does RGS6 upregulation or D2 autorecepto